TH23219A - Various formulas for the treatment of complications of diabetes. - Google Patents
Various formulas for the treatment of complications of diabetes.Info
- Publication number
- TH23219A TH23219A TH9501001515A TH9501001515A TH23219A TH 23219 A TH23219 A TH 23219A TH 9501001515 A TH9501001515 A TH 9501001515A TH 9501001515 A TH9501001515 A TH 9501001515A TH 23219 A TH23219 A TH 23219A
- Authority
- TH
- Thailand
- Prior art keywords
- acid
- treatment
- dgla
- gla
- complications
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract 6
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract 5
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 3
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract 3
- 229940114079 arachidonic acid Drugs 0.000 claims abstract 3
- 229940072107 ascorbate Drugs 0.000 claims abstract 3
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract 3
- 239000011668 ascorbic acid Substances 0.000 claims abstract 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 239000000600 sorbitol Substances 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 235000021081 unsaturated fats Nutrition 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 230000037041 intracellular level Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000009117 preventive therapy Methods 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- -1 ascorbate ester Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 abstract 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 abstract 1
- 229960002733 gamolenic acid Drugs 0.000 abstract 1
- 230000000774 hypoallergenic effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Abstract
การใช้ แฟทที แอซิด ที่ถูกทำให้ไม่อิ่มตัวที่ตำแหน่ง-6ก-6, โดยเฉพาะอย่างยิ่ง แกมมาลินอเลนิค แอซิด (GLA), ได โฮโมแกมมาลินอเลนิค แอซิด (DGLA) หรือ อราคิดอนิค แอซิด (ZZ), ร่วมกันกับ วัสดุที่สามารถยอมรับได้ทางเภสัชกรรม ที่ ลดระดับภายในเซลล์ต่างๆ ของซอร์บิทอลในร่างกาย, โดยเฉพาะ อย่างยิ่ง สารยับยั้ง แอสโดส ริดัคเทส, ในการบำบัดของ (รวม ถึงการบำบัดป้องกัน) และในการเตรียมสารยาสำหรับการบำบัดของ (รวมถึง การบำบัดป้องกัน), โรคแทรกซ้อนระยะยาวต่างๆ ของเบา หวาน (diabetes mellitus) สูตรผสมทางเภสัชกรรมต่างๆ ของ วัสดุต่าง ๆ เช่นนั้น แอสคอร์เบท เอสเทอร์ ต่างๆ ของ แฟทที แอซิด ที่ถูกทำให้ไม่อิ่มตัวทีตำแหน่ง-6 ก-6 (นอก เหนือจาก GLA หรือ DGLA) โดยภายใน สิทธิบัตรยา The use of unsaturated fat acid at position -6a-6, especially Gamma linolenic acid (GLA), dihomogamma linolenic acid (DGLA) or arachidonic acid (ZZ), in combination with materials capable of Pharmacologically acceptable to lower levels within cells. Of sorbitol in the body, in particular asdosridicase inhibitors, in the therapy of (including preventive therapy) and in the preparation of medicinal substances for the treatment of (including Preventive therapy), long-term complications of diabetes mellitus, various pharmaceutical formulations of such materials; ascorbate ester of hypoallergenic acid Saturation to position -6A-6 (other than GLA or DGLA) by within the drug patent
Claims (3)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH23219A true TH23219A (en) | 1997-01-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960000219A (en) | Compositions for the treatment of diabetes complications | |
| DK0724885T3 (en) | Pernasal composition and pernasal preparation containing this | |
| EG19642A (en) | A process for the preparation of oral composition for the treatment of inflammatory bowel diseases | |
| EP0151989A3 (en) | Means for the treatment of cardiac diseases | |
| KR940018089A (en) | Prevention and treatment for radiation damage of internal tissue | |
| BR9401199A (en) | Drug preparations, process for the preparation of a medicine preparation, process for the preparation of a medicine formulation. | |
| WO2000041504A3 (en) | Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides | |
| KR880007073A (en) | medicine | |
| AU1300001A (en) | Gastroresistant tablets for alimentary, dietetic and therapeutic use | |
| KR880007074A (en) | medicine | |
| DE58906232D1 (en) | Controlled drug delivery containing azelastine. | |
| DE69401502D1 (en) | Pharmaceutical preparation for producing a stabilized powder which contains a combination of acetylsalicylic acid and metoclopramide as the active ingredient | |
| EP0341810A3 (en) | Use of phytic acid as an antidote for alcohol and poisons | |
| AU1860895A (en) | Drug for relieving side effects caused by immunosuppressants | |
| FR2437832A1 (en) | MEDICAMENT BASED ON P-TOLYL DIIODOMETHYLSULFONE USEFUL IN PARTICULAR FOR THE TREATMENT OF SKIN INFECTIONS CAUSED BY YEAST AND MUSHROOMS | |
| CA2018227A1 (en) | Association of physiologically dosed vitamin a and of various active principles having a therapeutical activity | |
| JPS646214A (en) | Remedy for ulcerative colonopathy | |
| HK8994A (en) | Medicament for treatment of pregnancy-induced hypertension | |
| RU95110776A (en) | COMPOSITION FOR THE TREATMENT OF DIABETES COMPLICATIONS, USE OF 6-DESATURATED H-6 FATTY ACID FOR THE TREATMENT OF DIABETES COMPLICATIONS, METHOD FOR PRODUCING A MEDICINE, ASCORBENE ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUM ESSENTIUS | |
| RU93016030A (en) | A MEDICINE STIMULATING THE GRANULOSITARY GROWTH OF HEMATOPHONYA IN CYTOSTATIC MYELODEPRESSIONS | |
| KR910004181A (en) | New Pharmaceutical Oral Dosage Forms That Increase In Vivo Effectiveness | |
| DE69211743D1 (en) | Medicinal product containing aureobasidine | |
| IE780730L (en) | Veterinary composition | |
| IL110888A0 (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative | |
| Nivet | CASES OF CYSTICERCUS FINNUS OF THE BRAIN. |